Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBIBP-CorV Immuno-bridging Study in Children vs Adults
NCT04917523Phase 3Completed
- Sponsor
- China National Biotec Group
- Start
- Jul 2021
- Primary completion
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of BBIBP-CorV in coronavirus disease 2019 (COVID-19), sponsored by China National Biotec Group. Started Jul 2021; status: completed.
02
Drugs
BBIBP-CorV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04917523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04917523.